Epigral Limited has informed the stock exchanges of the availability of the audio recording from its conference call discussing Q4 FY2026 financial results. The conference call was held on Saturday, 2 May 2026 at 4:30 p.m., and the disclosure was filed with the exchanges on 3 May 2026.

Regulatory Compliance Disclosure

The communication was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule-III Part-A thereof. Epigral has submitted the filing to both the National Stock Exchange of India Limited and BSE Limited, requesting the exchanges to record the information and disseminate it to their members.

Audio Recording Availability

The audio recording of the Q4 FY2026 results conference call has been made publicly accessible through the company's official website. The key details of the disclosure are summarised below:

The filing was signed by Gaurang Trivedi, Company Secretary & Compliance Officer (M. No. A22307), on behalf of Epigral Limited, headquartered at Epigral Tower, Behind Safal Profitaire, Corporate Road, Prahladnagar, Ahmedabad 380015, Gujarat, India.

Epigral Limited has filed its audited financial results for Q4FY26 with the National Stock Exchange and BSE Limited under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The company reported highest ever quarterly revenue of ₹736.16 crore and recommended a final dividend of ₹5 per share, representing 50% of face value of ₹10. The Board meeting was held on May 2, 2026, at the registered office in Ahmedabad.

Conference Call Recording Available

Following the Q4FY26 results announcement, Epigral Limited has made available the audio recording of the conference call discussing the quarterly results. The conference call was held on Saturday, May 2, 2026 at 4:30 p.m. In compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, the company has provided access to the audio recording through its official website. The recording is available at the company's results section and provides detailed discussions on the Q4FY26 performance.

Operational Performance Highlights

The company demonstrated strong operational metrics with 15% sequential sales volume growth and plant utilization exceeding 80% in Q4FY26. This operational efficiency contributed significantly to the revenue recovery and improved financial performance during the quarter. The Derivatives & Specialty business contributed 54% of revenue in Q4FY26 compared to 52% in Q3FY26.

Q4FY26 Financial Performance

The fourth quarter demonstrated exceptional performance with revenue reaching ₹736.16 crore, marking a 17% YoY growth from ₹627.63 crore in Q4FY25. On sequential basis, the company witnessed strong recovery with 22% QoQ growth from ₹597.12 crore in Q3FY26. PAT stood at ₹81.93 crore for the quarter, showing 109% QoQ improvement from ₹39.15 crore in Q3FY26. EBITDA for the quarter was ₹169 crore with a margin of 23%.

FY2026 Annual Performance and Capex Plans

For the full year, revenue stood at ₹2,542.16 crore, a 1% decline from ₹2,565.34 crore in FY2025 due to a 4% drop in sales volume. PAT for FY26 was ₹333.01 crore compared to ₹356.70 crore in FY25. The company spent ₹394.15 crore on capital expenditure in FY2026, with expansion projects progressing as per schedule. CPVC Resin capacity will reach 1,50,000 TPA by adding 75,000 TPA, while Epichlorohydrin capacity will reach 1,00,000 TPA by adding 50,000 TPA, both expected to be commissioned in H1FY27.

Management Commentary and Strategic Outlook

Maulik Patel, Chairman and Managing Director, highlighted the strong operational performance driven by 15% sequential volume growth and improved plant utilization above 80%. Patel noted that demand recovery began in November and strengthened through Q4, with momentum expected to continue into FY27 subject to global macro conditions. The company has also invested in renewable energy through agreements with Pro-Zeal Green Power Ten Private Limited for a 19.80 MW Wind Solar Hybrid Power Plant in Gujarat.

Regulatory Filing and Recognition

The audited financial results were approved by the Board on May 2, 2026, and filed by Company Secretary & Compliance Officer Gaurang Trivedi. The statutory auditors M/s. S R B C & CO LLP issued audit reports with unmodified opinion. Epigral has been awarded the EcoVadis Silver Medal and its Responsible Care certification has been renewed for another three years. The company is expanding its Wind Solar Hybrid Power Plant capacity to 38.14 MW by adding 19.80 MW, demonstrating commitment to sustainable operations.